Eimeria Necatrix is a coccidian parasite that causes intestinal coccidiosis in poultry, leading to significant economic losses in the poultry industry worldwide. It is a highly prevalent pathogen that causes severe damage to the intestinal mucosa, leading to impaired nutrient absorption and growth retardation. Developing effective control strategies against this pathogen is, therefore, crucial to minimize economic losses and improve animal welfare. In recent years, significant progress has been made in understanding the pathogenic mechanisms of Eimeria Necatrix, particularly the role of its various antigens in host-parasite interactions. One such antigen is the NPmz19 protein, which has gained considerable attention in recent years for its potential in developing effective vaccines against Eimeria Necatrix.

The NPmz19 protein is a surface antigen that is expressed by sporozoites, the invasive stage of the parasite. Sporozoites are responsible for invading host cells and establishing infection in the host’s intestine. The NPmz19 protein is a highly conserved antigen that has been found to be essential for the parasite’s survival and pathogenicity. Studies have shown that antibodies against the NPmz19 protein can significantly reduce parasite invasion and replication in host cells, highlighting the potential of this antigen in developing effective vaccines against Eimeria Necatrix.

The potential of the NPmz19 protein in developing effective vaccines against Eimeria Necatrix has been explored in several studies. These studies have shown that immunization with the NPmz19 protein can induce significant levels of protective immunity against Eimeria Necatrix infection. The resulting immune response is characterized by the production of specific antibodies that can recognize and neutralize the parasite, leading to reduced parasite invasion and replication in host cells. The use of the NPmz19 protein in developing effective vaccines against Eimeria Necatrix, therefore, holds promise in minimizing economic losses and improving animal welfare in the poultry industry.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

The application of Eimeria necatrix cDNA and recombinant antigen in diagnosis of Eimeria necatrix infection can be used in both polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) tests. PCR is a powerful tool for the diagnosis of Eimeria necatrix as it can detect the presence of the parasite in samples from infected animals. ELISA is a more sensitive test than PCR and can detect the presence of specific antigens from the parasite. The use of cDNA and recombinant antigens can help to improve the accuracy of the PCR and ELISA tests for the diagnosis of Eimeria necatrix.